Navigation Links
BioMed Realty, L.P. Announces Closing of Offering of 3.85% Senior Unsecured Notes Due 2016
Date:3/30/2011

SAN DIEGO, March 30, 2011 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its operating partnership subsidiary, BioMed Realty, L.P., completed a public offering of $400 million aggregate principal amount of 3.85% Senior Notes due 2016 (the "Notes").  The Notes are senior unsecured obligations of the operating partnership and are fully and unconditionally guaranteed by BioMed Realty Trust, Inc.  

Interest on the Notes is payable semiannually on April 15 and October 15, beginning October 15, 2011. The Notes will mature on April 15, 2016.  The Notes were issued at 99.365% of the principal amount, with a coupon of 3.85%, to yield 3.99% to maturity.  The operating partnership intends to use the net proceeds from the offering to repay a portion of the outstanding indebtedness under its unsecured line of credit and for other general corporate and working capital purposes.

The registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities, blue sky, or other laws of such state or other jurisdiction. Wells Fargo Securities, LLC, KeyBanc Capital Markets Inc., and Morgan Stanley & Co. Incorporated acted as Joint Book Running Managers for the offering.  A final prospectus supplement related to the offering was filed with the Securities and Exchange Commission on March 24, 2011.  A copy of the final prospectus supplement may be obtained by contacting Wells Fargo Securities, LLC, 1525 West W.T. Harris Blvd., NC0675, Charlotte, North Carolin
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston University Biomedical Engineers Find Chink in Bacterias Armor
2. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
3. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
4. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
5. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
6. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
7. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
8. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
9. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
10. Voler Systems President Speaks at BIOMEDevice San Jose
11. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  RESMED INC. (NYSE: RMD ... and fiscal year ended June 30, 2014 results on Thursday, ... close. A press release with ResMed,s results will be issued ... host a webcast to discuss operating results and future outlook. ... 1:30 p.m. US Pacific Time and the live webcast of ...
(Date:7/10/2014)...  BC Technical, the largest nationwide, non-OEM provider of ... a leading provider of Siemens Nuclear Medicine and Molecular ... BC Technical as the authorized provider of service and ... BC Technical announced today that the two companies have ... the service and systems provider for MiE,s camera systems. ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Oct. 17, 2011 Archimedes Pharma Ltd., and its ... (fentanyl) nasal spray is now available by prescription in ... breakthrough pain in cancer patients 18 years of age ... tolerant to opioid therapy for their underlying persistent cancer ...
... Calif., Oct. 17, 2011 Abaxis, Inc. (NasdaqGS: ABAX), a ... a conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on Tuesday, ... the second quarter of fiscal year 2012 after the market ...
Cached Medicine Technology:Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 3Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 4Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 5Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 6Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 7Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2
(Date:7/10/2014)... 10, 2014 Ivalua, the global ... of the 4th “Trending in Procurement” report on ... , Every day multinational corporations process thousands of ... etc. To meet this challenge, more and more ... can be defined as a suite of integrated ...
(Date:7/10/2014)... Most professional football players who have shoulder stabilization surgery ... study finds. Shoulder instability is a common injury ... surgery to fix the problem has been unclear, the ... players who had shoulder stabilization surgery. Ninety percent of ... defined as playing in at least one regular season ...
(Date:7/10/2014)... who have a vasectomy may be at increased risk ... But the risk is comparatively small, the researchers acknowledged. ... more research is needed to determine if the study ... researchers analyzed data from more than 49,400 American men ... During that time, 6,023 cases of prostate cancer were ...
(Date:7/10/2014)... Medical Service (EMS) responders felt better prepared to respond ... training according to a new study in the journal ... first study to specifically examine the EMS provider comfort ... shooter has not yet been neutralized or working with ... as the Columbine High School shooting, the Virginia Tech ...
(Date:7/10/2014)... obesity is one of the top public health concerns ... aged 2-19 classified as obese as of 2012. As ... organizations have taken to Twitter to discuss the problem. ... PhD, assistant professor at the Brown School at Washington ... hashtag #childhoodobesity in tweets to track Twitter conversations about ...
Breaking Medicine News(10 mins):Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:Study looks at how Twitter can be used to address specific health issues 2
... due to non-recurring event in 2007, net loss stable ... Canadian dollars unless otherwise noted), BELLEVILLE, ON, Nov. ... research-based, technology-driven Canadian,biopharmaceutical company, today announced financial results for ... 30, 2007. "We are also focused on the ...
... Reduce Debt and Enhance Financial Flexibility To Fund ... ... Balance, Inc.,(Nasdaq: SMBL ) today announced its results for the third ... 2007, the Company,reported net sales of approximately $42 million and a net ...
... HALL, N.C., EXTON, Pa. and SAN DIEGO, Nov. ... southeastern US,provider of oncology equipment sales and service, ... alliance with Radiology Oncology Systems, Inc.,(ROS), an oncology ... Acceletronics, Inc., a US provider of oncology equipment ...
... and ... Product Portfolio, LA JOLLA, Calif., ... today announced that,it has raised $33.9 million in a Series B ... round were Frazier,Healthcare Ventures and Alloy Ventures, along with founding investor ...
... Charged with Illegally Distributing over 12 Million Narcotic ... United States,Attorney Matt M. Dummermuth announced today that ... distribute controlled substances through an,Internet pharmacy and with ... in an Indictment filed today in United States ...
... Nov. 8 Cash Technologies, Inc.,(Amex: TQ ) ... American,Stock Exchange (the "Exchange" or "AMEX") notified Cash Tech ... certain of the Exchange,s continued,listing standards as set forth ... Guide). Specifically, Cash Tech is not in compliance with ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9Health News:Bioniche Reports Fiscal 2008 First Quarter 10Health News:Bioniche Reports Fiscal 2008 First Quarter 11Health News:Smart Balance Announces Third Quarter 2007 Results 2Health News:Smart Balance Announces Third Quarter 2007 Results 3Health News:Smart Balance Announces Third Quarter 2007 Results 4Health News:Smart Balance Announces Third Quarter 2007 Results 5Health News:Smart Balance Announces Third Quarter 2007 Results 6Health News:Smart Balance Announces Third Quarter 2007 Results 7Health News:Smart Balance Announces Third Quarter 2007 Results 8Health News:Smart Balance Announces Third Quarter 2007 Results 9Health News:Smart Balance Announces Third Quarter 2007 Results 10Health News:Smart Balance Announces Third Quarter 2007 Results 11Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 2Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 3Health News:$40 Million Forfeiture Sought in Nation-Wide Internet Pharmacy Case 2Health News:Cash Technologies Discusses AMEX Listing Requirements 2Health News:Cash Technologies Discusses AMEX Listing Requirements 3Health News:Cash Technologies Discusses AMEX Listing Requirements 4
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
... has been designed to enhance fixation in ... hole configurations. The objective of the product ... primary modes: Tilt, migration and rotation. The ... initial and long-term fixation. The porous coating ...
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: